Eledon Pharmaceuticals, Inc. stock is down -0.54% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 February’s closed higher than January.
Eledon Pharmaceuticals, Inc. focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS.
Unlock Exclusive Market Insights! Receive timely updates on market developments. Sign up & stay informed!